LumaCina is a fully integrated global supplier of sterile injectable pharmaceutical drugs located in Perth Australia. LumaCina supplies sterile injectable pharmaceutical drugs, spanning high potency, blow fill seal, multi format vials and more, all manufactured in Perth Australia, to customers in Australia, New Zealand, Asia and Northern Europe. LumaCina's core portfolio consists of legacy Pfizer medicines, manufactured in Australia to the highest quality standards and trusted by hospitals across the region.
Bridgewest Group established LumaCina business unit under Bridgewest Perth Pharma in Perth, Australia on April 25, 2023. The team and facility have a 30-year history of producing high quality injectables with supply reliability and an exemplary regulatory record, most recently under the ownership of Pfizer (Perth) Pty Ltd. According to LinkedIn, LumaCina was founded in 2023 and operates with 11-50 employees.
Recent Leadership News
On July 14, 2026, LumaCina announced the appointment of Gary Bird as Chief Executive Officer, appointed by Executive Chair Mark Crotty, who will continue to lead LumaCina's long-term strategy. Bird brings more than three decades of leadership experience across the Australian pharmaceutical industry, with deep expertise in commercial strategy, market expansion and partnership-led growth, and over the past 13 years has led companies including Orion Pharma, Medreich and Meda.
Facts compiled by Executive Moves from publicly available news and press releases on 15 July 2026. Spotted an inaccuracy? Email us and we'll review within 1 business day.
To upgrade to a Premium Profile reach out to us at info@executive-moves.com.
Are you on the LumaCina team?
This is a Light company page, auto-generated from public news coverage. Claim it to verify the company description, add logo and links, and control how your organisation is represented on Executive Moves.
Claim this company →
